Scale

AM (pre-dose)

AM (post-dose)

PM (pre-dose)

PM (post-dose)

** ARCI-A
Plc/Plc1
Plc/SYN115


1 (1-2)
2 (1-4)


1 (0-2)
2 (1-4)


1 (0-1)
2 (1-4)


1 (0-1)
3 (2-5)

ARCI-PCAG
Plc/Plc1
Plc/SYN115


4 (4-7)
4 (1-4)


7 (4.8-8)
4 (1-4)


5.03 (4-8)
4 (3-7)


5 (4-8)
4 (3-6

ARCI-MGB
Plc/Plc1
Plc/SYN115


1 (0-2)
3 (0-6)


2 (0-3)
4 (0-8)


1 (1-2)
2 (0-8)


1 (0-2)
2 (1-8)

ARCI-BG
Plc/Plc1
Plc/SYN115


4 (3-5)
5 (4-6)


4 (3-5)
6 (4-8)


4 (3-5)
5 (4-7)


4 (3-4)
5 (4-7)

ARCI-LSD

Plc/Plc1
Plc/SYN115



3 (2-4)
2.8 (2-3)

 

3.1 (3-4)
3 (2-4)



4 (3-4)
3.3 (3-4)



4 (4-4)
3 (3-5)

* VAS “any effect”
Plc/Plc1
Plc/SYN115


2 (0-4)
4 (1-21)


2 (0-8)
6 (0-20)


2 (0-6)
10 (7-32)


7 (2-15)
15 (10-95)

*, ** VAS “good effects”
Plc/Plc1
Plc/SYN115


1 (0-5)
5 (2-23)


4 (2-13)
13 (2-30)


4 (0-10)
11 (7-34)


5 (3-19)
88 (16-107)

* VAS “bad effects”
Plc/Plc1
Plc/SYN115


0 (0-3)
4 (0-7)


3 (0-3)
0 (0-6)


0 (0-3)
8 (0-11)


3 (0-6)
12 (6-63)

** VAS “like effect”
Plc/Plc1
Plc/SYN115


1 (0-3)
6 (2-63)


4 (0-8)
11 (5-69)


5 (1-11)
12 (5-61)


5 (0-6)
77 (13-92)

VAS “friendly”
Plc/Plc1
Plc/SYN115


109 (0-114)
128 (5-158)


110 (4-122)
56 (0-171)


112 (0-125)
22 (6-128)


96 (7-118)
119 (47-171)

* VAS “confused”
Plc/Plc1
Plc/SYN115


1 (0-3)
4 (0-8)


4 (0-5)
3 (1-5)


3 (0-3)
8 (3-23)


4 (2-11)
7 (4-20)

VAS “able to concentrate”
Plc/Plc1
Plc/SYN115



128 (118-151)
175 (134-209)



114 (114-151)
134 (100-145)



114 (55-118)
123 (114-188)



114 (94-134)
150 (118-194)

** VAS “excited”
Plc/Plc1
Plc/SYN115


3 (0-13)
109 (7-115)


5 (4-55)
55 (5-122)


4 (0-6)
57 (25-119)


7 (5-114)
108 (23-119)

** VAS “alert”
Plc/Plc1
Plc/SYN115


114 (91-117)
137 (106-158)


105 (18-112)
125 (112-156)


59 (2-119)
156 (114-188)


79 (31-119)
139 (111-170)

VAS “relaxed”
Plc/Plc1
Plc/SYN115


114 (102-131)
136 (115-159)


108 (26-151)
123 (108-176)


113 (9-133)
130 (114-176)


79 (21-184)
122 (110-165)

* indicates significant within-subject result (time), p < .05
** indicates significant between-group result (dose condition), p < .05
Table 2: Pre- and post-dose subjective effects measures (ARCI, VAS) across two groups of dosing conditions (Placebo AM / SYN115 PM, 13 subjects = Plc/SYN115) or (Placebo AM / Placebo PM, 9 subjects = Plc/Plc). Data show medians and interquartile ranges.
Goto home»